Gemini Therapeutics announced a disease registry and natural history study to identify and characterize disease progression in patients with non-central geographic atrophy secondary to dry age-related macular degeneration, according to a press release.
Thousands of subjects will be genetically screened to assess genetic loci across high-risk genetic variants associated with dry AMD, and hundreds will be enrolled in one of two studies based on genetic criteria, the release said.
CLARITY1 will evaluate long-term clinical outcomes and disease progression in those who are carriers of functionally
Uncategorized